Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial

BMC Pharmacology and Toxicology

Volumn 15, Issue 1, 2014, Pages

  Mandala, Justin ^a   Nanda, Kavita ^a   Wang, Meng ^a   De Baetselier, Irith ^b   Deese, Jennifer ^a   Lombaard, Johan ^c   Owino, Fredrick ^d   Malahleha, Mookho ^e   Manongi, Rachel ^f   Taylor, Douglas ^a   Van Damme, Lut ^a,g  

^a FAMILY HEALTH INTERNATIONAL   (United States)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^c JOSHA Research   (South Africa)

^d IMPACT RESEARCH AND DEVELOPMENT ORGANIZATION   (Kenya)

^e Setshaba Research Centre   (South Africa)

^f KILIMANJARO CHRISTIAN MEDICAL CENTRE   (Tanzania)

^g BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

Africa; Emtricitabine; HIV; Pre exposure prophylaxis; Safety; Tenofovir disoproxil fumarate; Women

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; PHOSPHORUS; PLACEBO; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DEOXYCYTIDINE; EMTRICITABINE; PHOSPHONIC ACID DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

ADULT; AFRICAN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG SAFETY; FEMALE; HEPATITIS B VIRUS; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; NEPHROTOXICITY; PATIENT COMPLIANCE; PHOSPHATE BLOOD LEVEL; PRE-EXPOSURE PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; ADOLESCENT; ANALOGS AND DERIVATIVES; BLACK PERSON; BLOOD; CHEMICALLY INDUCED; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG-INDUCED LIVER INJURY; HIV INFECTIONS; KIDNEY DISEASE; YOUNG ADULT;

ADENINE; ADOLESCENT; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ALANINE TRANSAMINASE; ANTI-HIV AGENTS; ASPARTATE AMINOTRANSFERASES; CREATININE; DEOXYCYTIDINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DRUG-INDUCED LIVER INJURY; EMTRICITABINE; FEMALE; HIV INFECTIONS; HUMANS; KIDNEY DISEASES; ORGANOPHOSPHONATES; PHOSPHORUS; PRE-EXPOSURE PROPHYLAXIS; REVERSE TRANSCRIPTASE INHIBITORS; TENOFOVIR; YOUNG ADULT;

EID: 84924353393     PISSN: 20506511     EISSN: 20506511     Source Type: Journal    
DOI: 10.1186/2050-6511-15-77     Document Type: Article

References (22)

1. Baeten JM, Haberer JE, Liu AY, Sista N: Preexposure prophylaxis for HIV prevention: where have we been and where are we going? J Acquir Immune Defic Syndr 2013,63(Suppl 2):S122-S129.
2. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapia M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O, Fernandez T, Veloso VG, Buchbinder SP, Chariyalertsak S, Schechter M, Bekker LG, Mayer KH, Kallas EG, Amico KR, Mulligan K, Bushman LR, Hance RJ, Ganoza C, Defechereux P, Postle B, Wang F, McConnell JJ, Zheng JH, Lee J, et al.: Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010, 363(27):2587-2599. 10.1056/NEJMoa1011205
3. Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, Chiamwongpaet S, Kitisin P, Natrujirote P, Kittimunkong S, Chuachoowong R, Gvetadze RJ, McNicholl JM, Paxton LA, Curlin ME, Hendrix CW, Vanichseni S: Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013, 381(9883):2083-2090. 10.1016/S0140-6736(13)61127-7
4. Celum C, Baeten JM: Antiretroviral-based HIV-1 prevention: antiretroviral treatment and pre-exposure prophylaxis. Antivir Ther 2012, 17(8):1483-1493. 10.3851/IMP2492
5. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, Henderson FL, Pathak SR, Soud FA, Chillag KL, Mutanhaurwa R, Chirwa LI, Kasonde M, Abebe D, Buliva E, Gvetadze RJ, Johnson S, Sukalac T, Thomas VT, Hart C, Johnson JA, Malotte CK, Hendrix CW, Brooks JT: Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012, 367(5):423-434. 10.1056/NEJMoa1110711
6. Karras A, Lafaurie M, Furco A, Bourgarit A, Droz D, Sereni D, Legendre C, Martinez F, Molina JM: Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003, 36(8):1070-1073. 10.1086/368314
7. Peyriere H, Reynes J, Rouanet I, Daniel N, de Boever CM, Mauboussin JM, Leray H, Moachon L, Vincent D, Salmon-Ceron D: Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 2004, 35(3):269-273. 10.1097/00126334-200403010-00007
8. Gaspar G, Monereo A, Garcia-Reyne A, de Guzman M: Fanconi syndrome and acute renal failure in a patient treated with tenofovir: a call for caution. AIDS (London, England) 2004, 18(2):351-352. 10.1097/00002030-200401230-00035
9. Kinai E, Hanabusa H: Progressive renal tubular dysfunction associated with long-term use of tenofovir DF. AIDS Res Hum Retrovir 2009, 25(4):387-394. 10.1089/aid.2008.0202
10. Horberg M, Tang B, Towner W, Silverberg M, Bersoff-Matcha S, Hurley L, Chang J, Blank J, Quesenberry C Jr, Klein D: Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. J Acquir Immune Defic Syndr 2010, 53(1):62-69. 10.1097/QAI.0b013e3181be6be2
11. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, Malahleha M, Owino F, Manongi R, Onyango J, Temu L, Monedi MC, Mak'Oketch P, Makanda M, Reblin I, Makatu SE, Saylor L, Kiernan H, Kirkendale S, Wong C, Grant R, Kashuba A, Nanda K, Mandala J, Fransen K, Deese J, Crucitti T, Mastro TD, Taylor D: Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012, 367(5):411-422. 10.1056/NEJMoa1202614
12. NIAID, Division of AIDS: The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. Bethesda, MD, USA: National Institute of Allergy and Infectious Diseases, Division of AIDS; 2004. December 28
13. Adams JL, Sykes C, Menezes P, Prince HM, Patterson KB, Fransen K, Crucitti T, De Baetselier I, Van Damme L, Kashuba AD: Tenofovir diphosphate and emtricitabine triphosphate concentrations in blood cells compared with isolated peripheral blood mononuclear cells: a new measure of antiretroviral adherence? J Acquir Immune Defic Syndr 2013, 62:260-266. 10.1097/QAI.0b013e3182794723
14. Berger L: Sigma diagnostics: pioneer of kits for clinical chemistry. Clin Chem 1993,39(5):902-903.
15. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kakia A, Odoyo J, Mucunguzi A, Nakku-Joloba E, Twesigye R, Ngure K, Apaka C, Tamooh H, Gabona F, Mujugira A, Panteleeff D, Thomas KK, Kidoguchi L, et al.: Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012, 367(5):399-410. 10.1056/NEJMoa1108524
16. Tarantino G, Conca P, Basile V, Gentile A, Capone D, Polichetti G, Leo E: A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. Hepatol Res 2007, 37(6):410-415. 10.1111/j.1872-034X.2007.00072.x
17. Tarantino G, Minno MNDD, Capone D: Durg-induced liver injury: is it somehow foreseeable? World J Gastroenterol 2009, 15(23):2817-2833. 10.3748/wjg.15.2817
18. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130(6):461-470. 10.7326/0003-4819-130-6-199903160-00002
19. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F: Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006, 145(4):247-254. 10.7326/0003-4819-145-4-200608150-00004
20. Calza L, Vanino E, Magistrelli E, Salvadori C, Cascavilla A, Colangeli V, Di Bari MA, Manfredi R, Viale P: Prevalence of renal disease within an urban HIV-infected cohort in northern Italy. Clin Exp Nephrol 2013,18(1):104-112.
21. Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, Beniowski M, Gatell J, Phillips AN, Ledergerber B, Lundgren JD: Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS (London, England) 2010, 24(11):1667-1678. 10.1097/QAD.0b013e328339fe53
22. Rodriguez-Novoa S, Alvarez E, Labarga P, Soriano V: Renal toxicity associated with tenofovir use. Expert Opin Drug Saf 2010, 9(4):545-559. 10.1517/14740331003627458